You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for metformin hydrochloride; pioglitazone hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00062764 ↗ Treating Nonalcoholic Steatohepatitis With Pioglitazone Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2003-06-01 Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol. The etiology of NASH is unclear, but it is commonly associated with diabetes, obesity, and insulin resistance. Several pilot studies, including a study of pioglitazone at the NIH Clinical Center (01-DK-0130), have shown that the insulin-sensitizing thiazolidinediones lead to decreases in serum alanine aminotransferase (ALT) levels and improved liver histology. Once therapy is stopped, however, ALT levels rapidly return to pre-treatment values. Inaddition we are currently enrolling patients with NASH in a pilot study of metformin therapy for 48-weeks, however our results in 3 patients thus far have not been very encouraging. In the current study, patients who have completed the pilot study of pioglitazone and have been off therapy for 48 weeks will be offered re-treatment for 3 years. We also propose to treat patients who have not had a satisfactory response to metformin with pioglitazone for the same duration. After a repeat medical and metabolic evaluation and liver biopsy, patients with moderate-to-severe NASH (activity score greater than or equal to 4) will restart pioglitazone at a dose of 15 mg daily. If after 48 weeks, ALT levels are not normal or improved to the degree identified during the pilot study, the dose will be increased to 30 mg daily at the end of 3 years, all patients will undergo repeat medical and metabolic evaluation and liver biopsy. The primary end point will be improvement in liver histology. Secondary end points will be improvements in insulin sensitivity, reduction in visceral fat, liver volume, and liver biochemistry. The aim of this study is to evaluate whether long-term pioglitazone therapy can safely achieve and maintain biochemical and histological improvements in NASH. ...
NCT00063232 ↗ Treating Nonalcoholic Steatohepatitis (NASH) With Metformin Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2003-06-01 Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance. At present, there are no approved treatments for NASH patients, but an experimental approach has focused on improving their insulin sensitivity. Metformin is one of the most commonly used medications for the treatment of diabetes. The purpose of this study is to determine whether the medical problems of NASH patients, specifically liver damage, improves when their insulin sensitivity is enhanced with metformin. The study will last 3 to 5 years and will enroll up to 30 patients. Participants will undergo a complete medical examination, a series of lab tests, and a liver biopsy. They will then start taking a single 500-mg tablet of metformin once a day for 2 weeks, then the same dosage twice a day for 2 more weeks, if they tolerate the first dosage. The dosage will increase to 1,000 mg twice a day for the remaining 44 weeks of the study. After 1 year, participants will undergo a repeat medical examination and liver biopsy.
NCT00097279 ↗ Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2004-08-01 This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood glucose.
NCT00108615 ↗ Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed US Department of Veterans Affairs Phase 4 2004-01-01 Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.
NCT00108615 ↗ Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed VA Office of Research and Development Phase 4 2004-01-01 Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for metformin hydrochloride; pioglitazone hydrochloride

Condition Name

Condition Name for metformin hydrochloride; pioglitazone hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 31
Type 2 Diabetes Mellitus 30
Type 2 Diabetes 24
Diabetes Mellitus 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for metformin hydrochloride; pioglitazone hydrochloride
Intervention Trials
Diabetes Mellitus 104
Diabetes Mellitus, Type 2 99
Fatty Liver 15
Non-alcoholic Fatty Liver Disease 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for metformin hydrochloride; pioglitazone hydrochloride

Trials by Country

Trials by Country for metformin hydrochloride; pioglitazone hydrochloride
Location Trials
United States 786
Germany 44
Canada 40
India 40
Mexico 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for metformin hydrochloride; pioglitazone hydrochloride
Location Trials
Texas 36
Florida 30
California 30
North Carolina 27
Georgia 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for metformin hydrochloride; pioglitazone hydrochloride

Clinical Trial Phase

Clinical Trial Phase for metformin hydrochloride; pioglitazone hydrochloride
Clinical Trial Phase Trials
Phase 4 67
Phase 3 43
Phase 2/Phase 3 3
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for metformin hydrochloride; pioglitazone hydrochloride
Clinical Trial Phase Trials
Completed 105
Unknown status 17
Recruiting 11
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for metformin hydrochloride; pioglitazone hydrochloride

Sponsor Name

Sponsor Name for metformin hydrochloride; pioglitazone hydrochloride
Sponsor Trials
Takeda 21
Novo Nordisk A/S 8
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 7
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for metformin hydrochloride; pioglitazone hydrochloride
Sponsor Trials
Other 137
Industry 86
NIH 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.